Dyadic International Inc splits its revenue into 3 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Grant at $837,252, 87% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4
|
1
|
1
|
1
|
1
|
1
|
0
|
1
|
2
|
| Grant |
2
share 64.9%
|
1
+66.4%
share 87.1%
|
0
+131.6%
share 43.9%
|
0
share 58.3%
|
1
share 69.9%
|
1
share 52.1%
|
0
share 53.5%
|
—
|
—
|
| License |
—
|
—
|
0
share 19.8%
|
0
-96.8%
share 2.7%
|
—
|
0
share 25.9%
|
—
|
0
share 56.9%
|
1
share 72.8%
|
| Research And Development Expenses |
1
-14.3%
share 28.9%
|
0
-42.0%
share 12.9%
|
0
+120.4%
share 36.3%
|
0
-37.3%
share 39.0%
|
0
-34.3%
share 30.1%
|
0
share 22.1%
|
0
share 46.5%
|
0
share 43.1%
|
1
share 27.2%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- DYAI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Jupiter, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1213809
- Former names
- CCP WORLDWIDE INC (until Nov 5, 2004)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.